Effectiveness and Safety of Reduced-Dose Enoxaparin in Non-ST-Segment Elevation Acute Coronary Syndrome Followed by Antiplatelet Therapy Alone for Percutaneous Coronary Intervention

American Journal of Cardiology

Volumn 100, Issue 9, 2007, Pages 1376-1382

  Denardo, Scott J ^a   Davis, Keith E ^b   Tcheng, James E ^c  

^a UNIVERSITY OF FLORIDA   (United States)

^b FirstHealth of the Carolinas Inc   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; HEPARIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACUTE CORONARY SYNDROME; AGED; ANTICOAGULANTS; ASPIRIN; ATHERECTOMY, CORONARY; CORONARY ANGIOGRAPHY; DRUG THERAPY, COMBINATION; ENOXAPARIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; STENTS; TICLOPIDINE;

EID: 35348872669     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.06.024     Document Type: Article

References (29)

1. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina) (2002). http://www.acc.org/clinical/guidelines/unstable/unstable.pdf Available at: http://www.acc.org/clinical/guidelines/unstable/unstable.pdf. Accessed on March 15, 2002
2. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention) (2005). http://www.acc.org/clinical/guidelines/percutaneous/update/index.pdf Available at: http://www.acc.org/clinical/guidelines/percutaneous/update/index.pdf. Accessed on September 1
3. Xiao Z., and Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 97 (1998) 251-256
4. Bijsterveld N.R., Peters R.J., Murphy S.A., Bernink P.J., Tijssen J.G., and Cohen M. Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes. Results from the Thrombolysis In Myocardial Infarction (TIMI) 11B and Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events (ESSENCE) studies. J Am Coll Cardiol 42 (2003) 2083-2089
5. Theroux P., Waters D., Lam J., Juneau M., and McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 327 (1992) 141-145
6. Smith A.J., Holt R.E., Fitzpatrick J.B., Palacios I.F., Gold H.K., Werner W., Bovill E.G., Fuster V., and Jang I.K. Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplasty. Am Heart J 131 (1996) 434-439
7. SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292 (2004) 45-54
8. Alexander K.P., Chen A.Y., Roe M.T., Newby L.K., Gibson C.M., Allen-La Pointe N.M., Pollack C., Gibler W.B., Ohman E.M., and Peterson E.D. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294 (2005) 3108-3116
9. Ashby D.T., Dangas G., Aymong E.A., Farkouh M.E., Mehran R., Lansky A.J., Moses J.W., Leon M.B., and Stone G.W. Relation between the degree of procedural anticoagulation and complications after coronary stent implantation. Am J Cardiol 92 (2003) 319-322
10. Brieger D.B., Mak K.H., Kottke-Marchant K., and Topol E.J. Heparin-induced thrombocytopenia. J Am Coll Cardiol 31 (1998) 1449-1459
11. Denardo S.J., Davis K.E., and Tcheng J.E. Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy. Am Heart J 149 (2005) 138-144
12. Braunwald E., Califf R.M., Cannon C.P., Fox K.A., Fuster V., Gibler W.B., Harrington R.A., King S.B., Kleiman N.S., Theroux P., et al. Redefining medical treatment in the management of unstable angina. Am J Med 108 (2000) 41-53
13. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Belmont Report: ethical principles and guidelines for the protection of human subjects of research. Fed Regist 44 (1979) 23192-23197
14. Dalby M., Montalescot G., Bal dit Sollier C., Vicaut E., Soulat T., Collet J.P., Choussat R., Gallois V., Drobinski G., Drouet L., and Thomas D. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel: results of the Platelet activity Extinction in non-Q-wave myocardial infarction with Aspirin, Clopidogrel, and Eptifibatide (PEACE) study. J Am Coll Cardiol 43 (2004) 162-168
15. Prevention of venous thromboembolism: international consensus statement (guidelines according to clinical evidence). Int Angiol 16 (1997) 3-38
16. Rao A.K., Pratt C., Berke A., Jaffe A., Ockene I., Schreiber T.L., Bell W.R., Knatterud G., Robertson T.L., and Terrin M.L. Thrombolysis In Myocardial Infarction (TIMI) Trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11 (1988) 1-11
17. Glantz S.A. Primer of Biostatistics (1992), McGraw-Hill, New York 188-217
18. de Winter R.J., Windhausen F., Cornel J.H., Dunselman P.H., Janus C.L., Bendermacher P.E., Michels H.R., Sanders G.T., Tijssen J.G., and Verheugt F.W. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 353 (2005) 1095-1104
19. Neumann F.J., Kastrati A., Pogatsa-Murray G., Mehilli J., Bollwein H., Bestehorn H.P., Schmitt C., Seyfarth M., Dirschinger J., and Schomig A. Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes. A randomized controlled trial. JAMA 290 (2003) 1593-1599
20. de Lemos J.A., Blazing M.A., Wiviott S.D., Brady W.E., White H.D., Fox K.A., Palmisano J., Ramsey K.E., Bilheimer D.W., Lewis E.F., et al. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. Eur Heart J 25 (2004) 1688-1694
21. CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before, during and after coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 349 (1997) 1429-1435
22. Denardo S.J., Davis K.E., Reid P.R., and Tcheng J.E. Efficacy and safety of minimal dose (≤1000 units) unfractionated heparin with abciximab in percutaneous coronary intervention. Am J Cardiol 91 (2003) 1-5
23. Stone G.W., Moliterno D.J., Bertrand M., Neumann F.J., Herrmann H.C., Powers E.R., Grines C.L., Moses J.W., Cohen D.J., Cohen E.A., et al. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET trial. Circulation 105 (2002) 2347-2354
24. Ferguson J.J., Antman E.M., Bates E.R., Cohen M., Every N.R., Harrington R.A., Pepine C.J., and Theroux P. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J 146 (2003) 628-634
25. Rajagopal V., Lincoff A.M., Cohen D.J., Gurm H.S., Hu T., Desmet W.J., Kleiman N.S., Bittl J.A., Feit F., and Topol E.J. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. Am Heart J 152 (2006) 149-154
26. Blankenship J.C., Sigmon K.N., Pieper K.S., O'Shea C., Tardiff B.E., and Tcheng J.E. Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT (Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II trial. Am J Cardiol 88 (2001) 969-973
27. Islam M.A., Blankenship J.C., Balog C., Iliadis E.A., Lincoff A.M., Tcheng J.E., Califf R.M., and Topol E.J. Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). Am J Cardiol 90 (2002) 916-921
28. The Fifth Organization of Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 (2006) 1464-1476
29. Martin J.L., Fry E.T., Sanderink G.J., Atherley T.H., Guimart C.M., Chevalier P.J., Ozoux M.L., Pensyl C.E., and Bigonzi F. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the Pharmacokinetics of Enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv 61 (2004) 163-170